Hexin Biotech

Hexin Biotech is a clinical-stage biotechnology company headquartered in Shanghai, China, dedicated to developing transformative gene therapies for patients with severe genetic and chronic diseases. Founded by industry veterans with experience at leading global gene therapy firms, the company utilizes a proprietary adeno-associated virus (AAV) platform to engineer optimized capsids and expression cassettes. Its lead program, HX001, is an AAV-based therapy for Hemophilia B that has received IND clearance and entered clinical trials. The company's pipeline also features advanced candidates for ophthalmic conditions like wet AMD and various central nervous system disorders, focusing on high-efficiency delivery and long-term therapeutic expression.